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Synthetic Procedures Chemicals
Unless otherwise indicated, reagents were obtained from commercial suppliers and used without further purification.
General Procedure for Preparation of Solenopsin Analogs
2,6-Dimethyl pyridine or 2,4,6-trimethyl pyridine (1.35 equiv.) was added dropwise to a stirred solution of n-BuLi (2M, 1.5 equiv.) in cyclohexane at 0 °C. After 30 min of stirring at 0 °C, the alkylbromide (1.0 equiv) was added dropwise and the reaction mixture was allowed to reach room temperature. The slurry was stirred at room temperature for another 4h, followed by addition of ice water. The obtained watermixture was extracted three times with ethyl acetate. The organic layers were combined and washed with brine, dried over MgSO 4 , filtered, and concentrated under reduced pressure. The crude compounds were purified by flash chromatography on silica gel. The resulting substituted pyridines (1.0 g) were reduced to the corresponding piperidines through catalytic hydrogenation at 50 psi for 12 hours in the presence of palladium (10 mol%) and rhodium on carbon (10 mol%) in absolute ethanol (80 mL). The mixture was filtered through Celite and concentrated under vacuum. The residue was passed through a short pad of silica, eluting with 20% (10% NH 4 OH:MeOH) in ethyl acetate, to give the products after concentration. 1 H NMR of compounds S11-S14 showed the presence of a single diastereomer. Based on the work of Pianaro et al, we expect the diastereomer to be the cis isomer (Pianaro et al., 2012) .
S11: 2,4-Dimethyl-6-nonadecylpiperidine
Compound S11 was prepared from 2.5 mL of 2,4,6-trimethyl pyridine (19 mmol) and 4.8 mL of 1-bromooctadecane (14 mmol) according to the general procedure. The crude 2,4-dimethyl-6-nonadecylpyridine was purified by flash chromatography (silica: ethyl acetate/hexanes 1:19), which afforded 2,4-dimethyl-6-nonadecylpyridine, the S11 precursor, as an off-white solid (3.71g, 71% yield BuLi, CH 3 (CH 2 ) 17 Br H 2 , Pd S11 S11 precursor S12: 2-Methyl-6-undecylpiperidine
Compound S12 was prepared from 3.0 mL of 2,6-dimethyl pyridine (26 mmol) and 4.0 mL of 1-bromodecane (19 mmol) according to the general procedure. The crude 2-methyl-6-undecylpyridine was purified by flash chromatography (silica: ethyl acetate/hexanes 1:9), which afforded 2-methyl-6-undecylpyridine, the S12 precursor, as a yellow oil (2.63 g, 60% yield S13: 2-Methyl-6-nonadecylpiperidine
Compound S13 was prepared from 2.2 mL of 2,6-dimethyl pyridine (19 mmol) and 4.8 mL of 1-bromooctadecane (14 mmol) according to the general procedure. The crude 2-methyl-6-nonadecylpyridine was purified by flash chromatography (silica: ethyl acetate/hexanes 1:9), which afforded 2-methyl-6-nonadecylpyridine, the S13 precursor, as an off-white solid (4.57g, 91% yield BuLi, CH 3 (CH 2 ) 17 Br H 2 , Pd S13 S13 precursor S14: 2-Methyl-6-pentadecylpiperidine Compound S14 was prepared from 2.2 mL of 2,6-dimethyl pyridine (19 mmol) and 4.1 mL of 1-bromopentadecane (14 mmol) according to the general procedure. The crude 2-methyl-6-pentadecylpyridine was purified by flash chromatography (silica: ethyl acetate/hexanes 1:20), which afforded 2-methyl-6-pentadecylpyridine, the S14 precursor, as a clear oil (4.2 g, 99% 
S15: 1-(Piperidin-2-yl)undecan-1-ol
Pyridine-2-carboxaldehyde (5.0 mL, 52 mmol) was added dropwise to a stirred solution of decylmagnesium bromide (52 mmol) in diethyl ether (52 mL) at 0 °C. The reaction mixture was allowed to reach room and after stirring at room temperature for an additional 4 h the reaction was quenched by addition of ice water. The mixture was extracted with diethyl ether, dried over MgSO 4 , filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel (ethyl acetate/hexanes 1:4), which afforded 1-(pyridin-2-yl)undecan-1-ol, the S15 precursor, as an off-white solid (4.5 g, 35% Hydrogenation according to the general procedure gave the product (S15) as a white solid (903 mg, 88%).
1 H NMR showed the product to be a 7:3 mixture of diastereomers. 
S15 precursor S15
Assessment of Anti Solenopsin A, and Analogs S11
The affect of ceramide, solenopsin A, and analogs cutaneous cell lines (primary HaCaTs, which are immortalized melanocyte, primary keratinocyte 50,000 cells/well, 20,000 cells/well in starting cell concentration are not significant to the experiment. with 20 µM of ceramide C2, 24 hours, followed by cell counting in quadruplicates. Of note, the primary keratinocytes were treated in serum free keratinocyte growth media. The primary melanocytes showed high toxicity to DMSO in serum-free media and were retested in complete melanocyte growth media. The Ha cells were also tested in complete 10% DMEM media.
a.
Assessment of Anti-Proliferative Activity for Ceramide, Solenopsin A, and Analogs S11-S15
, solenopsin A, and analogs S11-S15 was assessed on t primary melanocytes and primary keratinocytes), as well as on HaCaTs, which are immortalized hyperproliferative human keratinocytes.
keratinocyte, and HaCaT cells were plated at a concentration of cells/well, and 15,000 cells/well respectively. The differences starting cell concentration are not significant to the experiment. The cells were treated C2, (-)-solenopsin A, (+)-solenopsin A, or analogs followed by cell counting with a Coulter Counter. All compounds were tested Of note, the primary keratinocytes were treated in serum free . The primary melanocytes showed high toxicity to DMSO in free media and were retested in complete melanocyte growth media. The Ha cells were also tested in complete 10% DMEM media.
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for Ceramide, was assessed on two normal as well as on human keratinocytes. Primary cells were plated at a concentration of
The differences The cells were treated solenopsin A, or analogs S11-S15 for with a Coulter Counter. All compounds were tested Of note, the primary keratinocytes were treated in serum free . The primary melanocytes showed high toxicity to DMSO in free media and were retested in complete melanocyte growth media. The HaCat b.
c. Figure S1    Assessment of anti-S11-S15.
The anti-proliferative effect of ceramide C2, S11-S15 were evaluated in (a) melanocyte cells/well (Melanocytes), 20,000 cells/well 24 h with each compound. The first DMSO bar in each chart serves as control for (+) solenopsin A, and ceramide C2. The second DMSO bar is the control for S11 an average of four experiments ± s.d.
-proliferative activity for ceramide, solenopsin A, and analogs 
Akt activity and PDK1 activation -Cell Transfection and Imaging
Cell transfection and imaging was conducted as previously described (Gao et al., 2011; Gao and Zhang, 2008) . NIH 3T3 cells were plated and grown to 40% confluency. Cells were transfected with Lipofectamine 2000 and serum-starved for 24 hours and treated for 1 h with DMSO solutions of ceramide C2 (50 µM), (+)-solenopsin A (10 and 20 µM), (-)-solenopsin A (10 and 20 µM), and analogs S11-S15 (10 µM). For imaging, cells were washed with Hank's balanced salt solution buffer once quickly, and then imaged in dark at room temperature in HBSS supplemented with solenopsin derivatives at indicated concentrations. Platelet derived growth factor (PDGF, 50 ng/mL) was added to assess the effects of the compounds on PDGF-induced Akt activity and PDK1 activation, Images were acquired on a Zeiss Axiovert 200M microscope with a cooled charge-coupled device camera. Dual-emission ratio imaging was performed with a 420DF20 excitation filter, a 450DRLP dichroic mirror, and two emission filters, 475DF40 and 535DF25 for CFP and YFP, respectively. The data was analyzed with Metafluor 6.2 software (Universal Imaging, Downingtown, PA). Cell regions were selected and fluorescence images were background-corrected by deducting the background (regions with no cells) from the emission intensities of CFP or YFP. FRET ratio of regions of interest (ROI) at cell cytosol and at cell periphery representing the plasma membrane were used, respectively. All the ratios were normalized with the ratio before PDGF addition.
Determination of Cytotoxic Capacity of Solenopsin A and Analogs S12 and S14
A 3D cell culture of human skin keratinocytes was used to determine any potential toxicity of Solenopsin A and the analogs S12 and S14. Chemicals. Psoriasis tissue model was obtained from MatTek™ Corporation (Ashland, MA), USA. Scott's reagents (Harleco), Xylene (Harleco), Eosin (Sigma Aldrich), Hematoxylin (Sigma Aldrich), Ethyl alcohol (Sigma Aldrich), and Cytoseal-60 (RichardAllian) were used in H&E staining. Sample preparation. Solenopsin A (mixture of (+) and (-) isomers) and analogs S12 and S14 and were dissolved in water and subsequent dilutions were done to attain a physiological concentration of 10µM.
Determination of cytotoxicity by MTT assay
MTT reagent was added to the tissue inserts after 72 hours treatment and incubated for 3 hours at 37°C with 5% CO2. After 3 hours, MTT was extracted from the tissues by extractant solution and placing the tissues on a shaker for two hours. Absorbance of extracted solution was measured at 570nm. Viable tissues will convert MTT to a purple dye and amount of conversion is proportional to the viability of the tissues. Cell viability was calculated using a spreadsheet provided by MatTek; viability of less than 50% was determined to be irritant and cytotoxic. The results in Figure S2 show that solenopsin A and analogs S12 and S14 were not toxic to the cells and resulted in cell viability of 59.0 ± 5.98%, 83.2.2 ± 12.81% and 83.1 ± 13.46%, suggesting that the dose delivered was not toxic or irritant to the tissues. MTT assay was performed on the psoriatic tissue model to determine cytotoxicity of dose given to the tissue. (a) NC-Negative control (b) S12 analog (c) S14 analog (d) Solenopsin A. Dosed tissue was treated with MTT reagent and then extracted followed by analysis by absorbance at 570nm. Cell viability for solenopsin and analogs; S12 and S14 were found to be more than 50%. Experiment was carried with n=4 replicates and all values represent mean ± standard deviation (p value < 0.05).
H&E staining.
Tissues from the culture inserts were taken and embedded in OCT media and stored at -80 degrees. 7µm thick tissues sections were obtained by cryotome and Polysine slides were used for the histology. Tissues samples were fixed using 10% formaldehyde. All tissues were stained using Hematoxylin and Eosin; subsequent washing was done using water, 95% alcohol, acid alcohol and scott's reagent. Slides were stored in Xylene until sealed with cytostat-60. Acid alcohol solution was prepared by adding 2ml of HCL in 198ml of 70% EtOH. Images were viewed using Leica polarizing microscope and image analysis was done using ImageJ software.
Translocation of PTEN to Membrane Rafts
We noted the structural similarity between solenopsin and ceramide and therefore wanted to investigate if solenopsin also recruits PTEN to membrane rafts. To do this we used sucrose density gradient fractionation followed by western blotting. Caveolin was used as a positive marker to identify lipid raft fractions and an anti-PTEN antibody was used to identify PTEN-containing fractions ( Figure S1 ). A375 cells were treated for 1 h with 20 µM of (+)-solenopsin, (-)-solenopsin, or analogs S12-S15. Cells treated with only DMSO were used as a negative control and cells treated with 50 µM of ceramide were used as positive control. As expected, ceramide treated cells display a higher amount of PTEN in the lipid raft fractions (fraction 1-4) ( Figure S1 ). The compound with the largest amount of PTEN in the raft fractions was (-)-solenopsin A ( Figure S1 ). (+)-Solenopsin A and analog S12-treated cells showed similar amounts of PTEN in the raft fractions as the ceramide treated cells ( Figure S1 ). The rest of the analogs (S13-S15) appeared to have similar or even lower amounts of PTEN in lipid rafts as the control group ( Figure S1 ).
Sucrose Density Gradient Fractionation
Cells were grown in T-75 flasks until 80% confluent, followed by treatment for 1 h with 20 µM DMSO solutions of (+)-solenopsin A, (-)-solenopsin A, analogs (S12-S15), or 50 µM of ceramide C2. Lipid raft fractionation was performed with a 5-40% sucrose discontinuous gradient as previously described (Chen et al., 2011; Huang et al., 2010) . The A375 cells from each treatment group were subjected to mechanical disruption with 8 strokes of a homogenizer and lysed for 30 min on ice in 650 µL 0.5% Brij96 in TNEV buffer (10 mM Tris·HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 2 mM Na vanadate, and protease inhibitor cocktail). The homogenates were centrifuged at 1000 rpm for 1 min at 4 °C. Supernatant (500 µL) was diluted 1:1 with 80% sucrose in TNEV buffer and transferred to a centrifuge tube (13 × 51 mm). Next, a layer of 35% sucrose in TNEV buffer (3 mL) was carefully placed on top of the first layer, followed by a 5% sucrose layer in TNEV buffer (1 mL). The sucrose gradient tube was centrifuged at 34,000 rpm for 22 h at 4 °C in a Beckman SW 50.1 rotor. Figure S2 were quantified by densitometry analysis using 16). 
